Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1984-06

AUTHORS

Ulf Niemeyer, Jürgen Engel, Gerhard Scheffler, Klaus Molge, Dieter Sauerbier, Werner Weigert

ABSTRACT

The primary metabolite of cyclophosphamide (CP, 1), i.e. 4-hydroxy-CP 2, has high pharmacological activity, but it is a very unstable compound. Chemical approaches to the stabilization involved in the substitution of the hydroxy group at the C 4-position, especially by a sulfoalkylthio-moiety. Within this new class of compounds ASTA Z 7557 (2-(bis-(2-chloroethyl))-amino-cis-4-((2-sulfoethyl)-thio)-tetrahydro-2H-1,3,2-oxazaphosphorine-r-2-oxide cyclohexylamine salt, i.e. cis-4-sulfoethylthio-CP, cis-13) was chosen for further evaluation. Cis-13 was synthesized by condensation of compound 2 and 2-mercapto-ethanesulfonic acid cyclohexylamine salt 14 in aqueous acetone yielding the cis-isomer with high stereoselectivity. It is a white crystalline powder, m.p. 126–134°C, stable at room temperature, with a solubility of 16% in water. The stereochemistry was confirmed by NMR-data and X-ray diffraction. In 0.07 M phosphate buffer at pH 7 and 37°C cis-13 isomerizes to the epimer trans-13, equilibrating at a cis-trans-ratio of 59 to 41 within less than 5 minutes. Simultaneously a rapid initial hydrolysis occurs to 2 and 14 followed by a time period with lower degradation due to the decomposition of 2. The rate of release of 2 increases with decreasing concentration and especially by addition of an oxidant. It could be retarded by addition of the corresponding thiol mesna, sodium 2-mercapto-ethanesulfonate 15, or of another thiol. In the presence of 3-mercapto-propane sulfonate 13 yielded 4-(3-sulfopropyl)thio-CP17.With changing pH values from 2 to 9, the lowest hydrolytic speed was observed at pH 4.0 to 4.3. For clinical use cis-13 is prepared as a lyophilisate containing additional sodium citrate buffer to guarantee this optimal pH value. More... »

PAGES

133-139

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00232342

DOI

http://dx.doi.org/10.1007/bf00232342

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1053407036

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/6469506


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biotransformation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydrogen-Ion Concentration", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydrolysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kinetics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stereoisomerism", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Temperature", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Asta- Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Asta- Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Niemeyer", 
        "givenName": "Ulf", 
        "id": "sg:person.0624707177.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624707177.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Asta- Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Asta- Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Engel", 
        "givenName": "J\u00fcrgen", 
        "id": "sg:person.013744376512.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013744376512.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Asta- Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Asta- Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scheffler", 
        "givenName": "Gerhard", 
        "id": "sg:person.01131464741.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131464741.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Asta- Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Asta- Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Molge", 
        "givenName": "Klaus", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Asta- Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Asta- Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sauerbier", 
        "givenName": "Dieter", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Asta- Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Asta- Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Weigert", 
        "givenName": "Werner", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00262420", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049693978", 
          "https://doi.org/10.1007/bf00262420"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-94-009-6798-4_12", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048704109", 
          "https://doi.org/10.1007/978-94-009-6798-4_12"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1984-06", 
    "datePublishedReg": "1984-06-01", 
    "description": "The primary metabolite of cyclophosphamide (CP, 1), i.e. 4-hydroxy-CP 2, has high pharmacological activity, but it is a very unstable compound. Chemical approaches to the stabilization involved in the substitution of the hydroxy group at the C 4-position, especially by a sulfoalkylthio-moiety. Within this new class of compounds ASTA Z 7557 (2-(bis-(2-chloroethyl))-amino-cis-4-((2-sulfoethyl)-thio)-tetrahydro-2H-1,3,2-oxazaphosphorine-r-2-oxide cyclohexylamine salt, i.e. cis-4-sulfoethylthio-CP, cis-13) was chosen for further evaluation. Cis-13 was synthesized by condensation of compound 2 and 2-mercapto-ethanesulfonic acid cyclohexylamine salt 14 in aqueous acetone yielding the cis-isomer with high stereoselectivity. It is a white crystalline powder, m.p. 126\u2013134\u00b0C, stable at room temperature, with a solubility of 16% in water. The stereochemistry was confirmed by NMR-data and X-ray diffraction. In 0.07 M phosphate buffer at pH 7 and 37\u00b0C cis-13 isomerizes to the epimer trans-13, equilibrating at a cis-trans-ratio of 59 to 41 within less than 5 minutes. Simultaneously a rapid initial hydrolysis occurs to 2 and 14 followed by a time period with lower degradation due to the decomposition of 2. The rate of release of 2 increases with decreasing concentration and especially by addition of an oxidant. It could be retarded by addition of the corresponding thiol mesna, sodium 2-mercapto-ethanesulfonate 15, or of another thiol. In the presence of 3-mercapto-propane sulfonate 13 yielded 4-(3-sulfopropyl)thio-CP17.With changing pH values from 2 to 9, the lowest hydrolytic speed was observed at pH 4.0 to 4.3. For clinical use cis-13 is prepared as a lyophilisate containing additional sodium citrate buffer to guarantee this optimal pH value.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf00232342", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "2"
      }
    ], 
    "keywords": [
      "NMR-data", 
      "rapid initial hydrolysis", 
      "high pharmacological activity", 
      "white crystalline powder", 
      "optimal pH value", 
      "ray diffraction", 
      "compound 2", 
      "hydroxy group", 
      "chemical characterization", 
      "unstable compounds", 
      "crystalline powder", 
      "high stereoselectivity", 
      "salt 14", 
      "aqueous acetone", 
      "rate of release", 
      "phosphate buffer", 
      "pH value", 
      "stable derivatives", 
      "room temperature", 
      "new class", 
      "sodium citrate buffer", 
      "low degradation", 
      "pharmacological activities", 
      "initial hydrolysis", 
      "citrate buffer", 
      "primary metabolites", 
      "stereochemistry", 
      "diffraction", 
      "cis-13", 
      "oxidants", 
      "solubility", 
      "acetone", 
      "buffer", 
      "stereoselectivity", 
      "thiols", 
      "compounds", 
      "chemicals", 
      "derivatives", 
      "condensation", 
      "powder", 
      "water", 
      "hydrolysis", 
      "characterization", 
      "decomposition", 
      "substitution", 
      "temperature", 
      "degradation", 
      "stabilization", 
      "sodium", 
      "ASTA Z 7557", 
      "addition", 
      "concentration", 
      "metabolites", 
      "release", 
      "presence", 
      "values", 
      "ratio", 
      "activity", 
      "further evaluation", 
      "group", 
      "class", 
      "increase", 
      "rate", 
      "cyclophosphamide", 
      "trans-13", 
      "mesna", 
      "time period", 
      "evaluation", 
      "minutes", 
      "period", 
      "speed", 
      "compounds ASTA Z 7557", 
      "Z 7557", 
      "acid cyclohexylamine salt 14", 
      "cyclohexylamine salt 14", 
      "epimer trans-13", 
      "corresponding thiol mesna", 
      "thiol mesna", 
      "sulfonate 13", 
      "lowest hydrolytic speed", 
      "hydrolytic speed", 
      "clinical use cis-13", 
      "use cis-13", 
      "additional sodium citrate buffer"
    ], 
    "name": "Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide", 
    "pagination": "133-139", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1053407036"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00232342"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "6469506"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00232342", 
      "https://app.dimensions.ai/details/publication/pub.1053407036"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T17:56", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_178.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf00232342"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00232342'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00232342'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00232342'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00232342'


 

This table displays all metadata directly associated to this object as RDF triples.

214 TRIPLES      22 PREDICATES      120 URIs      110 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00232342 schema:about N349c86495cf34e4fabd7634b8caeb55c
2 N4e6784582ec7440382c52acb3dbf7046
3 N5c21bbbc7f914178a5a1abebf73a509c
4 N996e4de1a98f4a8d916280ef63101100
5 Nc40e14aa30f34e2b95a343818862d0d6
6 Ne2a0abcec3784525997d0d43dfb5d934
7 Nead0458939ad4227a69df92587055726
8 anzsrc-for:11
9 anzsrc-for:1115
10 schema:author N0bb7a1557fce4d3bb272e614845ce62a
11 schema:citation sg:pub.10.1007/978-94-009-6798-4_12
12 sg:pub.10.1007/bf00262420
13 schema:datePublished 1984-06
14 schema:datePublishedReg 1984-06-01
15 schema:description The primary metabolite of cyclophosphamide (CP, 1), i.e. 4-hydroxy-CP 2, has high pharmacological activity, but it is a very unstable compound. Chemical approaches to the stabilization involved in the substitution of the hydroxy group at the C 4-position, especially by a sulfoalkylthio-moiety. Within this new class of compounds ASTA Z 7557 (2-(bis-(2-chloroethyl))-amino-cis-4-((2-sulfoethyl)-thio)-tetrahydro-2H-1,3,2-oxazaphosphorine-r-2-oxide cyclohexylamine salt, i.e. cis-4-sulfoethylthio-CP, cis-13) was chosen for further evaluation. Cis-13 was synthesized by condensation of compound 2 and 2-mercapto-ethanesulfonic acid cyclohexylamine salt 14 in aqueous acetone yielding the cis-isomer with high stereoselectivity. It is a white crystalline powder, m.p. 126–134°C, stable at room temperature, with a solubility of 16% in water. The stereochemistry was confirmed by NMR-data and X-ray diffraction. In 0.07 M phosphate buffer at pH 7 and 37°C cis-13 isomerizes to the epimer trans-13, equilibrating at a cis-trans-ratio of 59 to 41 within less than 5 minutes. Simultaneously a rapid initial hydrolysis occurs to 2 and 14 followed by a time period with lower degradation due to the decomposition of 2. The rate of release of 2 increases with decreasing concentration and especially by addition of an oxidant. It could be retarded by addition of the corresponding thiol mesna, sodium 2-mercapto-ethanesulfonate 15, or of another thiol. In the presence of 3-mercapto-propane sulfonate 13 yielded 4-(3-sulfopropyl)thio-CP17.With changing pH values from 2 to 9, the lowest hydrolytic speed was observed at pH 4.0 to 4.3. For clinical use cis-13 is prepared as a lyophilisate containing additional sodium citrate buffer to guarantee this optimal pH value.
16 schema:genre article
17 schema:inLanguage en
18 schema:isAccessibleForFree false
19 schema:isPartOf N59931ea343414a4fbdc5f6fe5275c7ae
20 Ne20eea160eff4d7abe37ee802c90bdf9
21 sg:journal.1094201
22 schema:keywords ASTA Z 7557
23 NMR-data
24 Z 7557
25 acetone
26 acid cyclohexylamine salt 14
27 activity
28 addition
29 additional sodium citrate buffer
30 aqueous acetone
31 buffer
32 characterization
33 chemical characterization
34 chemicals
35 cis-13
36 citrate buffer
37 class
38 clinical use cis-13
39 compound 2
40 compounds
41 compounds ASTA Z 7557
42 concentration
43 condensation
44 corresponding thiol mesna
45 crystalline powder
46 cyclohexylamine salt 14
47 cyclophosphamide
48 decomposition
49 degradation
50 derivatives
51 diffraction
52 epimer trans-13
53 evaluation
54 further evaluation
55 group
56 high pharmacological activity
57 high stereoselectivity
58 hydrolysis
59 hydrolytic speed
60 hydroxy group
61 increase
62 initial hydrolysis
63 low degradation
64 lowest hydrolytic speed
65 mesna
66 metabolites
67 minutes
68 new class
69 optimal pH value
70 oxidants
71 pH value
72 period
73 pharmacological activities
74 phosphate buffer
75 powder
76 presence
77 primary metabolites
78 rapid initial hydrolysis
79 rate
80 rate of release
81 ratio
82 ray diffraction
83 release
84 room temperature
85 salt 14
86 sodium
87 sodium citrate buffer
88 solubility
89 speed
90 stabilization
91 stable derivatives
92 stereochemistry
93 stereoselectivity
94 substitution
95 sulfonate 13
96 temperature
97 thiol mesna
98 thiols
99 time period
100 trans-13
101 unstable compounds
102 use cis-13
103 values
104 water
105 white crystalline powder
106 schema:name Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide
107 schema:pagination 133-139
108 schema:productId N524b6e26025d4a15affe4bb7e553249a
109 N6b9db60c7bb642508acf6db3f38780d5
110 Ndae528531e6140e7beeace1d30f586f8
111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053407036
112 https://doi.org/10.1007/bf00232342
113 schema:sdDatePublished 2021-11-01T17:56
114 schema:sdLicense https://scigraph.springernature.com/explorer/license/
115 schema:sdPublisher N93ade6ce595b4b3389909881904aa306
116 schema:url https://doi.org/10.1007/bf00232342
117 sgo:license sg:explorer/license/
118 sgo:sdDataset articles
119 rdf:type schema:ScholarlyArticle
120 N061b14ec21be4e6480535ca9e56ef2f9 schema:affiliation grid-institutes:None
121 schema:familyName Molge
122 schema:givenName Klaus
123 rdf:type schema:Person
124 N0bb7a1557fce4d3bb272e614845ce62a rdf:first sg:person.0624707177.25
125 rdf:rest N69957d846d294e85a8f3d63526bb2ab6
126 N349c86495cf34e4fabd7634b8caeb55c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Biotransformation
128 rdf:type schema:DefinedTerm
129 N4e6784582ec7440382c52acb3dbf7046 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Stereoisomerism
131 rdf:type schema:DefinedTerm
132 N524b6e26025d4a15affe4bb7e553249a schema:name dimensions_id
133 schema:value pub.1053407036
134 rdf:type schema:PropertyValue
135 N59931ea343414a4fbdc5f6fe5275c7ae schema:volumeNumber 2
136 rdf:type schema:PublicationVolume
137 N5c21bbbc7f914178a5a1abebf73a509c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Kinetics
139 rdf:type schema:DefinedTerm
140 N69957d846d294e85a8f3d63526bb2ab6 rdf:first sg:person.013744376512.52
141 rdf:rest N8b7fefbccbd942a9823e7b0d58026c80
142 N6b9db60c7bb642508acf6db3f38780d5 schema:name doi
143 schema:value 10.1007/bf00232342
144 rdf:type schema:PropertyValue
145 N870a0e2a2a17418bb444ef25e53f9d21 rdf:first Nffc605f80c144dff96160a5b28723aa0
146 rdf:rest rdf:nil
147 N8b7fefbccbd942a9823e7b0d58026c80 rdf:first sg:person.01131464741.51
148 rdf:rest Ne1917c6bc58f4729b8cfa869d74db1aa
149 N93ade6ce595b4b3389909881904aa306 schema:name Springer Nature - SN SciGraph project
150 rdf:type schema:Organization
151 N99609a479aa942c1b78be8a7808c4dbe rdf:first Na277315f872d4dfba6dd61f490b6c4e4
152 rdf:rest N870a0e2a2a17418bb444ef25e53f9d21
153 N996e4de1a98f4a8d916280ef63101100 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Cyclophosphamide
155 rdf:type schema:DefinedTerm
156 Na277315f872d4dfba6dd61f490b6c4e4 schema:affiliation grid-institutes:None
157 schema:familyName Sauerbier
158 schema:givenName Dieter
159 rdf:type schema:Person
160 Nc40e14aa30f34e2b95a343818862d0d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Hydrogen-Ion Concentration
162 rdf:type schema:DefinedTerm
163 Ndae528531e6140e7beeace1d30f586f8 schema:name pubmed_id
164 schema:value 6469506
165 rdf:type schema:PropertyValue
166 Ne1917c6bc58f4729b8cfa869d74db1aa rdf:first N061b14ec21be4e6480535ca9e56ef2f9
167 rdf:rest N99609a479aa942c1b78be8a7808c4dbe
168 Ne20eea160eff4d7abe37ee802c90bdf9 schema:issueNumber 2
169 rdf:type schema:PublicationIssue
170 Ne2a0abcec3784525997d0d43dfb5d934 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Temperature
172 rdf:type schema:DefinedTerm
173 Nead0458939ad4227a69df92587055726 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Hydrolysis
175 rdf:type schema:DefinedTerm
176 Nffc605f80c144dff96160a5b28723aa0 schema:affiliation grid-institutes:None
177 schema:familyName Weigert
178 schema:givenName Werner
179 rdf:type schema:Person
180 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
181 schema:name Medical and Health Sciences
182 rdf:type schema:DefinedTerm
183 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
184 schema:name Pharmacology and Pharmaceutical Sciences
185 rdf:type schema:DefinedTerm
186 sg:journal.1094201 schema:issn 0167-6997
187 1573-0646
188 schema:name Investigational New Drugs
189 schema:publisher Springer Nature
190 rdf:type schema:Periodical
191 sg:person.01131464741.51 schema:affiliation grid-institutes:None
192 schema:familyName Scheffler
193 schema:givenName Gerhard
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131464741.51
195 rdf:type schema:Person
196 sg:person.013744376512.52 schema:affiliation grid-institutes:None
197 schema:familyName Engel
198 schema:givenName Jürgen
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013744376512.52
200 rdf:type schema:Person
201 sg:person.0624707177.25 schema:affiliation grid-institutes:None
202 schema:familyName Niemeyer
203 schema:givenName Ulf
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624707177.25
205 rdf:type schema:Person
206 sg:pub.10.1007/978-94-009-6798-4_12 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048704109
207 https://doi.org/10.1007/978-94-009-6798-4_12
208 rdf:type schema:CreativeWork
209 sg:pub.10.1007/bf00262420 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049693978
210 https://doi.org/10.1007/bf00262420
211 rdf:type schema:CreativeWork
212 grid-institutes:None schema:alternateName Asta- Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany
213 schema:name Asta- Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany
214 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...